CRISPR Therapeutics registers Phase 1/2 trial of CTX460 for Alpha-1 Antitrypsin Deficiency
The company is recruiting patients for a first-in-human study of its in vivo gene editing therapy CTX460 in severe AATD-related emphysema.
CRISPR Therapeutics has one trial update this week involving its investigational gene editing candidate CTX460.
- CTX460, a lipid nanoparticle formulation designed for in vivo gene editing of the SERPINA1 gene in adults with emphysema associated with severe alpha-1 antitrypsin deficiency1, is being tested in a Phase 1/2 trial that is currently recruiting. The study, sponsored by CRISPR Therapeutics, plans to enroll 68 participants1 and will test the drug via intravenous infusion1. The Phase 1 portion aims to determine safety and tolerability of CTX460 and the recommended Phase 2 dose1, while Phase 2 will assess absolute blood levels of total AAT at Month 61. The trial's estimated primary completion date is 2030-061.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.